Our strategy focuses on the development and production of innovative, high-quality and popular medical test systems and their implementation in the daily work of laboratories in Russia, the CIS and abroad. To date, only IMBIAN Group has a patent for one of the most advanced diagnostic test systems. Our multidisciplinary immunodiagnostic systems based on immunochips at a qualitatively new level solve the problems of early diagnosis, treatment and
prevention of many infectious diseases.
We provide favorable conditions for customers
We strive to work with partners so that all the latest medical test systems are available to laboratories and patients around the world. Reducing the cost of our kits to identify pathogens of viral and parasitic etiology leads to increased profits and profitability of laboratories using our test systems. The difference in price sometimes reaches 30% of the prices of Russia's largest producers. This mechanism makes it possible not only to build mutually beneficial long-
term cooperation, but also to ensure the availability of modern methods of laboratory diagnosis for all patients.
We control quality at each stage
IMBIAN Group of Companies has implemented a reliable system of product quality control: from its own biological and technical control department to clear work with accompanying documentation. Each product undergoes mandatory testing, compliance with the parameters is confirmed by certificates, declarations of conformity and registration certificates. It is important
for us to work honestly and conscientiously and we are confident in the quality of our product, so we are ready to provide samples for free testing to our customers.
We develop test systems for your tasks
Rapidly evolving, our test systems are changing in line with the changing demands of our customers. IMBIAN Group is one of the few in the Russian market that has the opportunity to develop medical test systems for the tasks and areas of testing set by the customer. The company's development department is ready to conduct research and develop a multiplex set
(immunochip) based on the customer's specifications, allowing simultaneous determination of up to eight or more analyzes in one sample, as well as to organize serial production of the required immunochip. Partnership, in our deep conviction, is the key to innovation with a high probability of success.